Guangzhou Percello Pharmaceutical

Percello Pharmaceutical is a biotechnology company headquartered in Guangzhou, China, focused on the discovery of small molecule drugs for challenging protein-protein interaction (PPI) targets. The company leverages a proprietary platform that combines fragment-based drug discovery (FBDD) with high-resolution X-ray crystallography and structural biology. Percello's research primarily targets deubiquitinating enzymes (DUBs) and other "undruggable" proteins involved in oncology and immunology. Its lead programs include inhibitors of USP7, aimed at treating various solid tumors. The company was founded by experienced scientists with backgrounds from Harvard Medical School and major pharmaceutical firms. Percello aims to bridge the gap between basic structural biology and clinical application to provide novel therapeutic options for patients.